232 related articles for article (PubMed ID: 15294075)
21. Construction of the dual-functional RNA ligand against HCV NS3 protease and helicase.
Fukuda K; Sekiya S; Kikuchi K; Funaji K; Kuno A; Hasegawa T; Nishikawa S
Nucleic Acids Res Suppl; 2001; (1):147-8. PubMed ID: 12836307
[TBL] [Abstract][Full Text] [Related]
22. Enzymatic properties of hepatitis C virus NS3-associated helicase.
Paolini C; De Francesco R; Gallinari P
J Gen Virol; 2000 May; 81(Pt 5):1335-45. PubMed ID: 10769077
[TBL] [Abstract][Full Text] [Related]
23. Structure-based mutational analysis of the hepatitis C virus NS3 helicase.
Tai CL; Pan WC; Liaw SH; Yang UC; Hwang LH; Chen DS
J Virol; 2001 Sep; 75(17):8289-97. PubMed ID: 11483774
[TBL] [Abstract][Full Text] [Related]
24. Nucleoside triphosphatase and RNA helicase activities associated with GB virus B nonstructural protein 3.
Zhong W; Ingravallo P; Wright-Minogue J; Skelton A; Uss AS; Chase R; Yao N; Lau JY; Hong Z
Virology; 1999 Sep; 261(2):216-26. PubMed ID: 10497107
[TBL] [Abstract][Full Text] [Related]
25. Structure/function analysis of an RNA aptamer for hepatitis C virus NS3 protease.
Sekiya S; Nishikawa F; Fukuda K; Nishikawa S
J Biochem; 2003 Mar; 133(3):351-9. PubMed ID: 12761171
[TBL] [Abstract][Full Text] [Related]
26. Helicase, a target for novel inhibitors of hepatitis C virus.
Yao N; Weber PC
Antivir Ther; 1998; 3(Suppl 3):93-7. PubMed ID: 10726059
[TBL] [Abstract][Full Text] [Related]
27. Role of the DExH motif of the Japanese encephalitis virus and hepatitis C virus NS3 proteins in the ATPase and RNA helicase activities.
Utama A; Shimizu H; Hasebe F; Morita K; Igarashi A; Shoji I; Matsuura Y; Hatsu M; Takamizawa K; Hagiwara A; Miyamura T
Virology; 2000 Aug; 273(2):316-24. PubMed ID: 10915602
[TBL] [Abstract][Full Text] [Related]
28. Specific interaction of hepatitis C virus protease/helicase NS3 with the 3'-terminal sequences of viral positive- and negative-strand RNA.
Banerjee R; Dasgupta A
J Virol; 2001 Feb; 75(4):1708-21. PubMed ID: 11160669
[TBL] [Abstract][Full Text] [Related]
29. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
30. PBDE: structure-activity studies for the inhibition of hepatitis C virus NS3 helicase.
Salam KA; Furuta A; Noda N; Tsuneda S; Sekiguchi Y; Yamashita A; Moriishi K; Nakakoshi M; Tani H; Roy SR; Tanaka J; Tsubuki M; Akimitsu N
Molecules; 2014 Apr; 19(4):4006-20. PubMed ID: 24699145
[TBL] [Abstract][Full Text] [Related]
31. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
[TBL] [Abstract][Full Text] [Related]
32. Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor.
Belon CA; High YD; Lin TI; Pauwels F; Frick DN
Biochemistry; 2010 Mar; 49(9):1822-32. PubMed ID: 20108979
[TBL] [Abstract][Full Text] [Related]
33. Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663.
Maga G; Gemma S; Fattorusso C; Locatelli GA; Butini S; Persico M; Kukreja G; Romano MP; Chiasserini L; Savini L; Novellino E; Nacci V; Spadari S; Campiani G
Biochemistry; 2005 Jul; 44(28):9637-44. PubMed ID: 16008349
[TBL] [Abstract][Full Text] [Related]
34. Unmasking the active helicase conformation of nonstructural protein 3 from hepatitis C virus.
Ding SC; Kohlway AS; Pyle AM
J Virol; 2011 May; 85(9):4343-53. PubMed ID: 21325413
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach.
Kandil S; Biondaro S; Vlachakis D; Cummins AC; Coluccia A; Berry C; Leyssen P; Neyts J; Brancale A
Bioorg Med Chem Lett; 2009 Jun; 19(11):2935-7. PubMed ID: 19414257
[TBL] [Abstract][Full Text] [Related]
36. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
Xue W; Wang M; Jin X; Liu H; Yao X
Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
[TBL] [Abstract][Full Text] [Related]
37. A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity.
Howe AY; Chase R; Taremi SS; Risano C; Beyer B; Malcolm B; Lau JY
Protein Sci; 1999 Jun; 8(6):1332-41. PubMed ID: 10386883
[TBL] [Abstract][Full Text] [Related]
38. Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).
Borowski P; Heising MV; Miranda IB; Liao CL; Choe J; Baier A
Biochem Pharmacol; 2008 Jul; 76(1):28-38. PubMed ID: 18479669
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of hepatitis C virus NS3 helicase by manoalide.
Salam KA; Furuta A; Noda N; Tsuneda S; Sekiguchi Y; Yamashita A; Moriishi K; Nakakoshi M; Tsubuki M; Tani H; Tanaka J; Akimitsu N
J Nat Prod; 2012 Apr; 75(4):650-4. PubMed ID: 22394195
[TBL] [Abstract][Full Text] [Related]
40. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
